Purpose: To present Swedish Macula Register (SMR) data regarding treatment of neovascular age-related macular degeneration (AMD) in clinical practice since 2008. Methods: A retrospective register-based study was conducted. Evaluation of baseline demographics, visual outcome and number of injections during this period is presented. Results: Mean age at diagnosis was 79 AE (SD) 8 years; 65% were female. The proportion of patients with <2 months' duration of symptoms increased from 26% in 2008 to 41% in 2014 (p = 0.001). Mean visual acuity (VA) at baseline increased from 54.3 AE 15.0 early treatment diabetic retinopathy study (ETDRS) letters in 2008 to 57.8 AE 15.6 letters in 2014 (CI 95 2.6; 4.3; p < 0.001). Mean VA after 1 year of treatment increased from 57.8 AE 17.7 ETDRS letters for patients who started the treatment in 2008 to 62.8 AE 16.4 ETDRS letters in patients starting treatment in 2014 (CI 95 2.67; 4.64; p < 0.001). During all study years, the proportion of patients with an improvement in VA of between 5 and 15 letters was around 30%, while 14% had VA improvement of more than 15 letters. The mean number of injections during the first treatment year increased from 4.3 AE 1.9 in 2008 to 5.9 AE 2.9 in 2014 (CI 95 1.40; 1.67; p < 0.001). Seven-year follow-up of 322 eyes showed a mean change of À1 letters from baseline, with a mean of 21 injections for the entire period. Conclusion: The duration of symptoms before treatment decreased, while VA at baseline and after 1 year of treatment increased over the years and so did the number of injections. Long-term follow-up demonstrated stable VA.
Introduction
The treatment for neovascular AMD has changed over the years, from administering photodynamic therapy (PDT), at the beginning of 2000, to treating with anti-vascular endothelial growth factor (anti-VEGF) after 2007 with the approval of ranibizumab (Rosenfeld et al. 2006; Brown et al. 2009 ). The European Medicines Agency (EMA) has approved two different drugs for treatment of neovascular AMD: ranibizumab (Lucentis Ò ; Genentech Inc., South San Francisco, CA, USA) and aflibercept (Eylea Ò ; Bayer Pharma AG, Berlin, Germany). In clinical practice, the off-label drug bevacizumab (Avastin Ò ; Genentech Inc., South San Francisco, CA, USA) is also administered to treat patients with neovascular AMD.
Treatment with anti-VEGF has been shown to be efficient not only in maintaining VA but also in improving visual outcome for all subtypes of choroidal neovascularization (CNV) secondary to AMD (Freund et al. 2013; Tah et al. 2015) . Introduction of anti-VEGF has been found to induce positive health economic effects. A Danish study reports a decrease after 2007 in patients going legally blind from wet AMD (Bloch et al. 2012) , and the same tendency has been observed in Sweden where referrals to a low-vision rehabilitation centre in northern Sweden have been shown to have decreased after introduction of anti-VEGF treatment (Granstam et al. 2016) .
The treatment protocol, according to the clinical trials, is monthly injections, but a pro re nata (PRN) regimen with monthly controls and injections as needed has also proved to be efficient in maintaining VA (Lalwani et al. 2009 ). However, the frequent controls and injections required will put both a financial burden on society and a logistic burden on the patients, the physicians and other healthcare professionals. A recent European study with real-world data from many European countries reports improved VA after three initial injections, followed by declining VA probably due to less frequent injections and undertreatment of the patients compared with the approved schedule for treatment (Holz et al. 2015) . The same tendency has been demonstrated in a recent Swedish study where 70 patients were followed for 3 years (Rung & L€ ovestam-Adrian 2013) . Visual acuity (VA) declined over the years owing to undertreatment, but factors related to quality of life did not decrease to the same extent.
In Sweden, anti-VEGF treatment for neovascular AMD is available for all residents and fully reimbursed within the public healthcare system. The SMR, a national quality register, in 2008 started collecting information about treatment of CNV with intravitreal injections. The register, funded by the Swedish Association of Local Authorities and Regions and the Swedish government, collects data from patients treated for CNV from most medical centres across Sweden for both quality improvement and research purposes. Neovascular AMD represents 97% of all diagnoses registered in the SMR. Between 2008 and 2015, a total of 21 572 patients with neovascular AMD were registered.
The aim of this study was to present real-world SMR data on patients treated for neovascular AMD during the period 2008-2015 in Sweden. Baseline demographics, visual outcome and the number of injections given to patients registered with the SMR during this period were evaluated.
Materials and Methods
This study was conducted in accordance with the tenets of the Declaration of Helsinki and was approved by the Lund University Ethical Board. Data were obtained from the SMR after approval from its steering committee.
Population and register
The proportion of patients registered in the SMR, in relation to the population at risk of neovascular AMD (people older than 69 years) in Sweden, was calculated using data from Statistics Sweden. In 2010, the SMR contained data from 0.5% of the Swedish population older than 69 years (Westborg et al. 2015) . In 2015, around 1.6% of the population at risk were included in the registry. In 2015, 39 of 41 eye clinics nationwide were using the SMR. The national coverage of the treatments and followup visits was around 80%, which means that approximately 80% of all patients in Sweden treated for neovascular AMD have records in the SMR. When attending the clinic, patients receive information about the register and only data on those patients who give consent for their data to be included in the register are collected.
Variables in and validation of the register
Visual acuity (VA) was measured using the ETDRS chart. Where VA had been measured using the Snellen chart, Snellen VA was converted into ETDRS VA, according to Gregori et al. (2010) . Visual acuity (VA) of hand movements and amaurosis were converted into ETDRS 0.001. Near VA was measured using the Jaeger chart at approximately 35 cm distance and addition of +3.0 to best-corrected visual acuity (BCVA). Results are reported in typographical points, the smallest point size being 4 points and the largest 24 points.
Baseline visit was defined as the first visit at which neovascular AMD was diagnosed, and treatment prescribed. The 1-year follow-up visit was defined as the last visit in the period 10-14 months after the baseline visit. The change in VA was defined as the difference between the VA baseline value and VA at the 1-year visit. Patients treated for neovascular AMD before their inclusion in the SMR were excluded from the analyses.
The SMR includes demographic data, and data on type of lesion, VA outcome and frequency of injections and clinical visits, as well as which drugs are given and adverse events per clinic across Sweden (see Table 1 ). The data collected in the SMR are regularly monitored to minimize errors in the database. Automatic data checks are performed when registering patients, and statistical validation studies are regularly performed to estimate the number of errors in the database. Recently, a validation study was performed by comparing patients' original medical records with the database for 116 randomly selected patients. Variables included in the validation study were as follows: sex, age, treated eye, visit date, VA of the treated eye measured with the Snellen and ETDRS charts, near VA of the treated eye, treatment drug, total number of received injections, and adverse events. The SMR estimates errors and missing values to be around 5, 1 and 13% for ETDRS, number of injections, and Snellen VA, respectively (Westborg et al. 2015) .
Statistical methods
Data were described using summary statistics such as mean and standard deviation. Proportions were compared using the chi-square test. To describe the average changes in VA, near VA and number of injections when comparing different registration years, linear regression models were employed. As some patients were bilateral cases, incorporation of this information in the model was performed using a cluster term. To calculate the change in number of patients without a complete membrane diagnosis at first visit, a logistic model was used. The statistical significance level was 5% for all the calculations. All calculations were performed using Stata/IC 13.1 for Windows (StataCorp, College Station, TX, USA).
Results
The In November 2012, aflibercept was approved, and during 2013-2015, a steady increase in the number of registered treatments with aflibercept was recorded in Sweden (Fig. 1) . Almost 70% of patients had a 1-year follow-up visit (12 AE 2 months from the diagnostic visit). Mean VA after 1 year of treatment increased from 57.8 AE 17.7 ETDRS letters for patients who started the treatment in 2008 to 62.8 AE 16.4 ETDRS letters for patients who started the treatment in 2014, an increase of 5.0 ETDRS letters (CI 95 3.76; 6.18; p = 0.001). In patients with complete follow-up, the mean difference in VA between the baseline visit and the 12-month follow-up visit was between 1.1 and 2.4 ETDRS letters for all years. The change in mean VA after 1 year of treatment was stable over the years, at 0.22 ETDRS letters per year (CI 95 0.04; 0.40; p = 0.015). The observed improvement in VA outcome during the last years is due to the better VA at baseline (Table 4) .
During all years, approximately 30% of the patients improved their VA by 5-15 letters, and 14% improved by more than 15 letters. On the other hand, approximately 17% of patients lost between 5 and 15 letters and 10% deteriorated by more than 15 letters. In all cases, only patients with complete follow-up have been included.
The reasons for discontinuing treatment during the first treatment year are listed in Table 5 . Over the study years, between 8% and 13% of patients discontinued treatment within 1 year. The most common reasons for discontinuing the treatment were stable or low VA. Additional patients were lost to follow-up due to failure to attend the clinic, deficient registration, treatment ended not registered, or VA not tested at every visit at clinic. 24% to 32% of eyes were discontinued or lost to follow-up over all years.
The number of injections given during the first year of treatment increased from mean 4.3 AE 1.9 in 2008 to 5.9 AE 2.9 injections in 2014 (p < 0.001; Table 6 ). For all years, the number of injections received by the patients varied between 1 and 16 injections. The mean age (79 years) and sex distribution (65% female) were similar in both cohorts (Table 7) . More patients in the 2012-2014 cohort compared with the 2008-2010 cohort had a symptom duration of less than 2 months before treatment, 42% versus 31%, p < 0.001. In the first cohort (2008) (2009) (2010) , only 10% of lesions were undiagnosed, compared with 17% in the second cohort, p < 0.001. The mean VA at baseline for eyes with complete followup was higher in the second compared with the first cohort: 60.1 AE 13.8 and 57.1 AE 14.2 ETDRS letters, respectively, a difference of 3.0 ETDRS letters (CI 95 2.55; 3.61; p < 0.001).
Follow-up after 1 year of treatment: treatment drug, visual outcome and number of injections
In 2008-2010, ranibizumab was used in 99% and bevacizumab in 1% of cases, whereas in 2012-2014, 50% of anti-VEGF treatments used ranibizumab, 25% bevacizumab and 25% aflibercept.
A 1-year visit (12 AE 2 months after the diagnostic visit) was registered for 72% (n = 4712) of eyes in cohort 1 and 72% (n = 6712) of eyes in cohort 2 (Table 7) . Mean VA for patients with complete follow-up after 1 year of treatment was 58.6 AE 17.6 ETDRS letters for patients in cohort 1 and 62.0 AE 16.8 ETDRS letters for patients in cohort 2. There was no difference in mean change in VA between the two cohorts, 1.5 versus 1.9 ETDRS letters (p = 0.214).
The percentage of eyes that improved their VA by 5-15 letters was 29% (n = 1352) and 32% (n = 2123) in the first and second cohort, respectively. The percentage of patients who improved their VA by more than 15 letters was 14% (n = 683) and 12% (n = 827) for the first and second cohort, respectively. On the other hand, the percentage of patients who lost between 5 and 15 letters was 16% (n = 781) and 16% (n = 1086) for the first and second cohort, respectively, and the percentage of patients who lost more than 15 letters was 12% (n = 547) and 10% (n = 647), respectively. In all cases, only patients with complete follow-up have been included.
Near VA for patients with complete follow-up improved from 12.1 AE 6.2 at baseline to 10.2 AE 6.2 at follow-up in cohort 1 and from 11.0 AE 6.0 to 9.4 AE 6.0 in cohort 2. The gain in near VA from baseline to 1 year later was significant (for cohort 2008-2010: À1.8 (CI 95 À2.1; À1.6); for cohort 2012-2014: À1.5 (CI 95 À1.7; À1.3), p < 0.001).
Frequency of injections
The mean number of injections given during the first treatment year increased from 5.1 AE 2.0 in cohort 1 to 6.1 AE 2.4 in cohort 2 for eyes with The first visit was defined as the visit at which the patient was diagnosed with neovascular age-related macular degeneration (AMD). PCV = polypoidal choroidal vasculopathy, RAP = retinal angiomatous proliferation, SD = standard deviation. complete follow-up, a difference of +1.0 injections (CI 95 0.9; 1.1; p = 0.001).
Patients without complete follow-up
There were 1802 (28%) and 2652 (28%) eyes in cohort 1 and cohort 2, respectively, in which the treatment was discontinued or lost to follow-up within 1 year. The main reasons for discontinuing the treatment were low or stable VA.
Patients followed for 7 years (2008) (2009) (2010) (2011) (2012) (2013) (2014) Anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular AMD was initiated in 1807 eyes (1607 patients) in 2008. As some patients discontinued the treatment before 7 years, data for patients with and without complete follow-up are shown. At the end of the seventh year, 322 eyes (18%) had completed follow-up. Patients with complete follow-up for 7 years were younger at baseline (mean age 75.4 AE 7.0 years and 69% female). Change in VA was defined as the difference between baseline VA and VA at the 1-year visit. The first visit was defined as the visit at which the patient was diagnosed with neovascular age-related macular degeneration (AMD). Patients with a complete 1-year follow-up had a visit 10-14 months after the first visit. Where a patient did not have a 1-year visit, the last registered visit after the first visit was counted as the 1-year visit; that is, last observation carried forward (LOCF) was applied. SD = standard deviation. Patients followed for 7 years showed a stable VA compared with baseline. The mean number of injections in the first year was 5 AE 2.0, and thereafter, a mean of two to three injections were given every year, with a cumulative number of 21 injections over 7 years. In the LOCF patients, the cumulative number was 9 injections.
Discussion
In this study, we describe how patients with neovascular AMD were treated in Sweden in the period 2008-2015. We can demonstrate stable VA in the first treatment year in most patients.
Mean improvement was between 1.1 and 2.4 ETDRS letters, which is lower compared with results reported in clinical trials (Freund et al. 2013) . However, our results are concordant with those reported in other European observational studies, such as the AURA, COMPASS and TWIN trials (Wolf & Kampik 2013; Holz et al. 2015; Souied et al. 2015) . The two phase III clinical trials, ANCHOR (patients with predominantly classic CNV) and MARINA (patients with minimally classic/occult CNV; Brown et al. 2009; Rosenfeld et al. 2006) , showed an improvement in VA after 1-year follow-up, of 11.3 and 7.2 letters, respectively, in patients with neovascular AMD treated with ranibizumab 0.5 mg compared with PDT. Later, the VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) trials (Schmidt-Erfurth et al. 2014 ) demonstrated that in patients Visual acuity (VA) is presented in Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Change in VA was defined as the difference between VA at baseline and VA at the 1-year visit. The first visit was defined as the visit at which the patient was diagnosed with neovascular age-related macular degeneration. Patients with a complete 1-year follow-up had a visit at 10-14 months from the first visit. Where a patient did not have a 1-year visit, the last registered visit after the first visit was counted as the 1-year visit; that is, last observation carried forward (LOCF) was applied. PCV = polypoidal choroidal vasculopathy, RAP = retinal angiomatous proliferation, SD = standard deviation.
with neovascular AMD, three initial monthly doses of intravitreal aflibercept 2.0 mg followed by bimonthly dosing could deliver outcomes comparable to monthly ranibizumab (0.5 mg), but with five fewer injections during the first year of treatment. In clinical practice, the off-label drug bevacizumab is also widely used to treat patients with neovascular AMD. Two clinical trials comparing ranibizumab and bevacizumab using different treatment regimens found that bevacizumab was not inferior to ranibizumab if applied with the same frequency (CATT study group; Martin et al. 2011; Chakravarthy et al. 2013) . After publication of the results, several counties in Sweden changed from ranibizumab to bevacizumab to reduce treatment costs. The number of injections given and visual outcome observed in the present study are comparable to results of the AURA trial (Holz et al. 2015) , which was an observational, multicountry study including 2227 patients treated with ranibizumab in standard clinical practice. The authors found that fewer injections were given in clinical practice (mean of five injections) compared with clinical trials and that the mean change in VA was +2.4 ETDRS letters after 1 year of treatment. The authors also found that more frequent visits and injections were associated with greater improvement in VA. This was not the case in the present study, where we observed an increase in number of injections given between the two times cohorts, but without any improvement in visual outcome. This discrepancy may be due to differences in the patient population and in the clinical routines in Sweden compared with the countries that participated in the AURA trial. Undertreatment can also be due to problems with resources and logistics. During PRN treatment, a low number of injections were administered in Sweden. This risk for undertreatment in PRN regime is also demonstrated by (Kvannli & Krohn 2017) , who also could show that switching to Treat and Extend regimen resulted in an increase in number of injections and an improved visual outcome. The same tendency has also been shown by Hatz & Pr€ unte (2017) . Thus, we speculate that the lack of improvement in VA, although an increase in injection frequency in later years, might be due to a non-consistent regimen where injections have been administered with too long intervals. Most clinics in Sweden have now introduced the Treat and Extend regimen, and it will be interesting to further explore the result of this in a couple of years. In our study, we could demonstrate that baseline VA increased from 2008 to 2014, most likely because a larger proportion of patients had shorter duration of symptoms before undergoing active treatment. Additionally, higher awareness for AMD symptoms among patients and in eye clinics might contribute to a more effective and faster diagnose and treatment. The importance of early treatment for visual outcome was addressed in a Danish study, where short symptom duration before start of treatment was independently correlated with better visual outcome at 3 months (Rasmussen et al. 2015) . A recent publication explored the initially untreated fellow eye with neovascular AMD in the ANCHOR and MARINA studies. These eyes were treated about 2 years later than the study eye, which resulted in a worse visual outcome, of 27.3 letters, compared with 54.7 letters in the promptly treated study eye (p = 0.001) (Bhisitkul et al. 2016) .
To determine subtypes of wet AMD, fluorescein and indocyanine green angiographies are required. While a subtyping of the AMD lesions was quite crucial during the PDT era, the unified treatment regimen of all lesions today has resulted in a diminished use of these examinations. We could demonstrate that the proportion of lesions without determination of subtype at baseline increased from 8-18% over the study years.
Further, we compared two cohorts to study differences in treatment between patients with treatment start during 2008-2010 and patients with treatment start during 2012-2014. As expected, VA at baseline and after 1-year follow-up was higher and the number of injections was increased in the later compared with the earlier cohort. The proportion of undiagnosed lesions was increased. The number of injections and the gain in VA in the first cohort (2008) (2009) (2010) was quite comparable to the TWIN Study, which reviewed cases in 2010-2011 (Souied et al. 2015) .
Reading ability and near vision function are important for patients, and our study shows a gain in near VA for both cohorts from baseline to 1-year follow-up. This is in accordance with a recent study of patients treated with aflibercept for neovascular AMD, which showed a more pronounced improvement in near vision compared with BCVA (Epstein & Amr en 2016).
The data recorded by the SMR give a unique opportunity to follow patients with neovascular AMD treated with anti-VEGF drugs over several years. In the present study, the 322 eyes followed and treated for 7 years received a mean number of 21 injections, and VA was stable.
There is limited information about the long-term effects of patients treated with intravitreal injections. The SEVEN-UP trial (Rofagha et al. 2013 ) evaluated VA at 7-8 years after initiation of ranibizumab therapy in 65 neovascular AMD patients who were originally treated in the ANCHOR and MAR-INA studies (Tah et al. 2015) and the open-label extension HORIZON trial (Singer et al. 2012 ). In the HORIZON study, the switch from a strict, monthly ranibizumab regimen to a more relaxed PRN regimen with less frequent followup resulted not only in worsening and progression of AMD in patients, but also in a decline in the VA gains achieved on the strict monthly dosing regimen. Patients from the SEVEN-UP trial received a mean of 1.6 injections per year since the end of the HOR-IZON study, and a mean of 6.8 injections during the last 3 years of the study, and had a mean VA of 54 letters (Bhisitkul et al. 2015) . Both the reported frequency of injections and the visual outcome are comparable to the present study. It is difficult to compare our results with those of the SEVEN-UP trial, however, as our patients were not recruited in a clinical trial and therefore received a lower total number of injections. However, the observed change in mean VA is within 5 letters, which could be considered as a stable development for the patients who remained in treatment.
Results from the Fight Retinal Blindness (FRB) outcome registry show a decrease of 2.6 letters below the baseline level after 5 years. The number of injections given was larger compared with our study, with a median of 6 injections during the first year and only a small decrease to 5 injections annually in the following years (Gillies et al. 2015) . Interestingly, at a mean of 7.3 years after ANCHOR or MARINA enrolment, macular atrophy was present in 98% of study eyes. As we have no information about macular atrophy in the present study population, no comparison is possible. However, it is important to consider the risk of developing atrophy in the treatment of neovascular AMD. A recent study from Munk et al. (2016) shows macular atrophy in a majority of patients with ≥30 anti-VEGF injections. In the present study, the reason for discontinuing the treatment was mostly because the disease was stable or VA was low, both of which may have been due to atrophy.
Our real-world study has several limitations. Clinical practice and decision to treat can differ between clinics in Sweden. The results presented are based on register data, which can be incomplete. In most cases, the estimated errors in the database were below 5%. Regarding VA, fewer errors were found when using ETDRS (5%) compared with Snellen (13%). In some cases, ETDRS values were converted from Snellen measurements, which can introduce errors, particularly at low VA. Our experience in previous analyses shows that the converted values do not affect the results.
The SMR is a database that is updated continuously, and therefore, the number of registered patients and visits changes over the year. Participation of clinics in the registry is voluntary, meaning that some clinics join while others leave the registry during this period. The data were real-world data reflecting real-world practices, with some patients discontinuing treatment before the 1-year follow-up, in most cases due to stable or low VA. Over the study period, 24-32% of eyes were discontinued or lost to follow-up before the 12-month review, and we addressed this by showing results for all patients with LOCF. In one study on SMRregistered patients starting treatment between 2010 and 2011, data obtained from the SMR were further linked to the Swedish People and Address Register (SPAR) managed by the Swedish tax office, to obtain information about the death date if applicable. Before the 1-year follow-up, 4% of patients had died (Westborg et al. 2017 ).
In conclusion, we present a summary of how patients with neovascular AMD were treated in Sweden during 2008-2015, including results for patients followed regularly for 7 years. We observed an increase in the number of patients who sought care with short-term duration of symptoms, and that VA at baseline and after 1 year of treatment improved over the years, while mean improvement in VA during the first treatment year remained stable over the study period. Furthermore, the number of registered injections increased. However, there is still a large difference between the number of injections given in standard health care and the treatment recommended by the pivotal trials with ranibizumab and aflibercept, and further studies on the optimal treatment frequency in clinical practice are needed. Therefore, we are planning to conduct additional analyses of data from the SMR regarding long-term outcomes of anti-VEGF treatment for neovascular AMD in clinical practice in Sweden.
